Clinical Topics & News

Delayed Coronary Vasospasm in a Patient with Metastatic Gastric Cancer Receiving FOLFOX Therapy

A 40-year-old man with stage IV gastric adenocarcinoma was found to have coronary artery vasospasm in the setting of recent 5-fluorouracil administration.

Author and Disclosure Information

 

References

Coronary artery vasospasm is a rare but well-known adverse effect of 5-fluorouracil (5-FU) that can be life threatening if unrecognized. Patients typically present with anginal chest pain and ST elevations on electrocardiogram (ECG) without atherosclerotic disease on coronary angiography. This phenomenon typically occurs during or shortly after infusion and resolves within hours to days after cessation of 5-FU.

In this report, we present an unusual case of coronary artery vasospasm that intermittently recurred for 25 days following 5-FU treatment in a 40-year-old male with stage IV gastric adenocarcinoma. We also review the literature on typical presentation and risk factors for 5-FU-induced coronary vasospasm, findings on coronary angiography, and management options.

5-FU is an IV administered antimetabolite chemotherapy commonly used to treat solid tumors, including gastrointestinal, pancreatic, breast, and head and neck tumors. 5-FU inhibits thymidylate synthase, which reduces levels of thymidine, a key pyrimidine nucleoside required for DNA replication within tumor cells.1 For several decades, 5-FU has remained one of the first-line drugs for colorectal cancer because it may be curative. It is the third most commonly used chemotherapy in the world and is included on the World Health Organization’s list of essential medicines.2

Cardiotoxicity occurs in 1.2 to 18% of patients who receive 5-FU therapy.3 Although there is variability in presentation for acute cardiotoxicity from 5-FU, including sudden death, angina pectoris, myocardial infarction, and ventricular arrhythmias, the mechanism most commonly implicated is coronary artery vasospasm.3 The direct observation of active coronary artery vasospasm during left heart catheterization is rare due its transient nature; however, several case studies have managed to demonstrate this.4,5 The pathophysiology of 5-FU-induced cardiotoxicity is unknown, but adverse effects on cardiac microvasculature, myocyte metabolism, platelet aggregation, and coronary vasoconstriction have all been proposed.3,6In the current case, we present a patient with stage IV gastric adenocarcinoma who complained of chest pain during hospitalization and was found to have coronary artery vasospasm in the setting of recent 5-FU administration. Following coronary angiography that showed a lack of atherosclerotic disease, the patient continued to experience episodes of chest pain with ST elevations on ECG that recurred despite cessation of 5-FU and repeated administration of vasodilatory medications.

Case Presentation

A male aged 40 years was admitted to the hospital for abdominal pain, with initial imaging concerning for partial small bowel obstruction. His history included recently diagnosed stage IV gastric adenocarcinoma complicated by peritoneal carcinomatosis status post initiation of infusional FOLFOX-4 (5-FU, leucovorin, and oxaliplatin) 11 days prior. The patient was treated for small bowel obstruction. However, several days after admission, he developed nonpleuritic, substernal chest pain unrelated to exertion and unrelieved by rest. The patient reported no known risk factors, family history, or personal history of coronary artery disease. Baseline echocardiography and ECG performed several months prior showed normal left ventricular function without ischemic findings.

Physical examination at the time of chest pain revealed a heart rate of 140 beats/min. The remainder of his vital signs were within normal range. There were no murmurs, rubs, gallops, or additional heart sounds heard on cardiac auscultation. Chest pain was not reproducible to palpation or positional in nature. An ECG demonstrated dynamic inferolateral ST elevations with reciprocal changes in leads I and aVL (Figure 1). A bedside echocardiogram showed hypokinesis of the septal wall. Troponin-I returned below the detectable level.

Electrocardiogram Obtained During Patient’s Initial Chest Pain Episode

The patient was taken for emergent coronary catheterization, which demonstrated patent epicardial coronary arteries without atherosclerosis, a left ventricular ejection fraction of 60%, and a right dominant heart (Figures 2 and 3). Ventriculogram showed normal wall motion. Repeat troponin-I several hours after catheterization was again below detectable levels.

Left and Right Coronary Artery System figure

Given the patient’s acute onset of chest pain and inferolateral ST elevations seen on ECG, the working diagnosis prior to coronary catherization was acute coronary syndrome. The differential diagnosis included other causes of life-threatening chest pain, including pulmonary embolism, pneumonia, aortic dissection, myopericarditis, pericardial effusion, cardiac tamponade, or coronary artery vasospasm. Computed tomography (CT) angiography of the chest was not consistent with pulmonary embolism or other acute cardiopulmonary process. Based on findings from coronary angiography and recent exposure to 5-FU, as well as resolution followed by recurrence of chest pain and ECG changes over weeks, the most likely diagnosis after coronary catheterization was coronary artery vasospasm.

Pages

Recommended Reading

How has the pandemic affected rural and urban cancer patients?
AVAHO
Surveillance after testicular cancer: New approaches slash radiation exposure
AVAHO
Bladder cancer indication withdrawn for durvalumab
AVAHO
Don’t delay: Cancer patients need both doses of COVID vaccine
AVAHO
FDA scrutinizes cancer therapies granted accelerated approval
AVAHO
Cancer screening stopped by pandemic: Repercussions to come?
AVAHO
Healthy lifestyle may offset genetic risk in prostate cancer
AVAHO
Personalized cancer vaccine shows early promise across tumor types
AVAHO
To stay: Two more cancer indications with ‘dangling approvals’
AVAHO
The power and promise of social media in oncology
AVAHO